Prognostic significance of preoperative C-reactive protein: albumin ratio in patients with clear cell renal cell carcinoma. 2015

Zhen Chen, and Yingjie Shao, and Min Fan, and Qianfeng Zhuang, and Kun Wang, and Wei Cao, and Xianlin Xu, and Xiaozhou He
Department of Urology, The Third Affiliated Hospital of Soochow University Changzhou 213003, P. R. China.

We undertook a retrospective analysis to evaluate the C-reactive protein/albumin (CRP/Alb) ratio for its prognostic value in patients with clear cell renal cell carcinoma (CCRCC). The study comprised 406 CCRCC patients undergoing nephrectomy between 2003 and 2012 in our hospital. The correlations among the pretreatment CRP/Alb ratio, clinicopathological parameters, and overall survival (OS) were evaluated. An elevated CRP/Alb ratio was associated with older age at surgery (P=0.007), more advanced TNM stage (P<0.001), more presence of tumor necrosis (P<0.001) and lymphovascular invasion (P<0.001), lower concentration of hemoglobin (P<0.001) and calcium (P=0.005), and shorter OS (P<0.001). The multivariate analysis confirmed that the CRP/Alb ratio independently predicted the OS of patients with CCRCC (P<0.001), the Glasgow Prognostic Score (GPS) (P=0.001) and modified GPS (mGPS) (P=0.019) were independent prognostic factors also. At last, we evaluated the prognostic value of the CRP/Alb ratio compared with the similar inflammation-based prognostic scores GPS and mGPS using the area under the curve (AUC). Although the differences were not statistically significant, the AUC value of the CRP/Alb ratio (continuous, categorical) was higher compared with the GPS and mGPS, except that the AUC value for the CRP/Alb ratio (categorical) at 3 years was lower than that for the GPS. The CRP/Alb ratio could take the place of the GPS and mGPS in terms of predicting prognosis in CCRCC.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D002292 Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. Adenocarcinoma, Renal Cell,Carcinoma, Hypernephroid,Grawitz Tumor,Hypernephroma,Renal Carcinoma,Adenocarcinoma Of Kidney,Adenocarcinoma, Renal,Chromophil Renal Cell Carcinoma,Chromophobe Renal Cell Carcinoma,Clear Cell Renal Carcinoma,Clear Cell Renal Cell Carcinoma,Collecting Duct Carcinoma,Collecting Duct Carcinoma (Kidney),Collecting Duct Carcinoma of the Kidney,Nephroid Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Cancer,Renal Cell Carcinoma,Renal Cell Carcinoma, Papillary,Renal Collecting Duct Carcinoma,Sarcomatoid Renal Cell Carcinoma,Adenocarcinoma Of Kidneys,Adenocarcinomas, Renal Cell,Cancer, Renal Cell,Carcinoma, Collecting Duct,Carcinoma, Collecting Duct (Kidney),Carcinoma, Nephroid,Carcinoma, Renal,Carcinomas, Collecting Duct,Carcinomas, Collecting Duct (Kidney),Carcinomas, Renal Cell,Collecting Duct Carcinomas,Collecting Duct Carcinomas (Kidney),Hypernephroid Carcinoma,Hypernephroid Carcinomas,Hypernephromas,Kidney, Adenocarcinoma Of,Nephroid Carcinomas,Renal Adenocarcinoma,Renal Adenocarcinomas,Renal Carcinomas,Renal Cell Adenocarcinoma,Renal Cell Adenocarcinomas,Renal Cell Cancers,Renal Cell Carcinomas,Tumor, Grawitz
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Zhen Chen, and Yingjie Shao, and Min Fan, and Qianfeng Zhuang, and Kun Wang, and Wei Cao, and Xianlin Xu, and Xiaozhou He
January 2021, Journal of cancer research and therapeutics,
Zhen Chen, and Yingjie Shao, and Min Fan, and Qianfeng Zhuang, and Kun Wang, and Wei Cao, and Xianlin Xu, and Xiaozhou He
March 2016, Anticancer research,
Zhen Chen, and Yingjie Shao, and Min Fan, and Qianfeng Zhuang, and Kun Wang, and Wei Cao, and Xianlin Xu, and Xiaozhou He
May 2019, Future oncology (London, England),
Zhen Chen, and Yingjie Shao, and Min Fan, and Qianfeng Zhuang, and Kun Wang, and Wei Cao, and Xianlin Xu, and Xiaozhou He
April 2021, Urologic oncology,
Zhen Chen, and Yingjie Shao, and Min Fan, and Qianfeng Zhuang, and Kun Wang, and Wei Cao, and Xianlin Xu, and Xiaozhou He
February 2011, Korean journal of urology,
Zhen Chen, and Yingjie Shao, and Min Fan, and Qianfeng Zhuang, and Kun Wang, and Wei Cao, and Xianlin Xu, and Xiaozhou He
January 2014, Urologia internationalis,
Zhen Chen, and Yingjie Shao, and Min Fan, and Qianfeng Zhuang, and Kun Wang, and Wei Cao, and Xianlin Xu, and Xiaozhou He
January 2022, Frontiers in surgery,
Zhen Chen, and Yingjie Shao, and Min Fan, and Qianfeng Zhuang, and Kun Wang, and Wei Cao, and Xianlin Xu, and Xiaozhou He
June 2018, World journal of surgery,
Zhen Chen, and Yingjie Shao, and Min Fan, and Qianfeng Zhuang, and Kun Wang, and Wei Cao, and Xianlin Xu, and Xiaozhou He
January 2017, OncoTargets and therapy,
Zhen Chen, and Yingjie Shao, and Min Fan, and Qianfeng Zhuang, and Kun Wang, and Wei Cao, and Xianlin Xu, and Xiaozhou He
July 2019, Future oncology (London, England),
Copied contents to your clipboard!